Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura (NYMC207)
The Use of Dose Dense Rituximab for High Risk Patients With Newly Diagnosed Acute Immune Thrombocytopenic Purpura
Sponsor: New York Medical College
A observational or N/A phase clinical study on Immune Thrombocytopenic Purpura, this trial is actively recruiting participants. The trial is conducted by New York Medical College and has accumulated 10 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Apr 16, 2026 — Present [daily]
Recruiting
Status: Unknown → Recruiting · Phase: PHASE1 → None
-
Nov 2025 — Apr 2026 [monthly]
Unknown PHASE1
Status: Recruiting → Unknown
-
Sep 2024 — Nov 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
Nov 2022 — Nov 2023 [monthly]
Recruiting PHASE1
-
Sep 2021 — Nov 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
-
Apr 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment. Correlative studies will be performed as outlined in the appendices. Quality of Life will be measured using the KIT as outlined in the protocol.
Contact Information
- New York Medical College
For direct contact, visit the study record on ClinicalTrials.gov .